Addex Therapeutics Ltd

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

Who: Addex/Indivior What: The companies have finally selected a clinical candidate each from their gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) research collaborati

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making. In December 2023, Scrip

With understanding of immune function advancing in leaps and bounds and a continuing proliferation of tools to manipulate it, expectations are high for advances in oncology and immunology over the com